Texas Bank & Trust Co Sells 619 Shares of Eli Lilly and Company $LLY

Texas Bank & Trust Co reduced its stake in Eli Lilly and Company (NYSE:LLY) by 14.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,623 shares of the company’s stock after selling 619 shares during the period. Eli Lilly and Company makes up 1.3% of Texas Bank & Trust Co’s portfolio, making the stock its 20th biggest position. Texas Bank & Trust Co’s holdings in Eli Lilly and Company were worth $3,332,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Peterson Wealth Services raised its position in shares of Eli Lilly and Company by 6.5% in the 1st quarter. Peterson Wealth Services now owns 4,902 shares of the company’s stock worth $4,508,000 after purchasing an additional 298 shares during the last quarter. Millstone Evans Group LLC grew its position in Eli Lilly and Company by 5.8% during the 1st quarter. Millstone Evans Group LLC now owns 1,165 shares of the company’s stock valued at $1,072,000 after purchasing an additional 64 shares during the last quarter. Main Street Research LLC grew its position in Eli Lilly and Company by 104.9% during the 1st quarter. Main Street Research LLC now owns 2,908 shares of the company’s stock valued at $2,674,000 after purchasing an additional 1,489 shares during the last quarter. First Horizon Corp increased its stake in Eli Lilly and Company by 20.4% during the 1st quarter. First Horizon Corp now owns 11,002 shares of the company’s stock valued at $10,119,000 after purchasing an additional 1,865 shares in the last quarter. Finally, Mosaic Family Wealth Partners LLC increased its stake in Eli Lilly and Company by 16.2% during the 1st quarter. Mosaic Family Wealth Partners LLC now owns 2,025 shares of the company’s stock valued at $1,862,000 after purchasing an additional 283 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Record use of GLP-1 drugs in the U.S. is supporting Eli Lilly’s best-selling obesity treatment business, with sales momentum accelerating for the company’s leading drug franchise. Record Numbers of Americans Are on GLP-1 Drugs. That’s Great News for This Stock.
• Positive Sentiment: Royal Bank of Canada raised its price target on LLY to $1,500 and kept an outperform rating, reinforcing Wall Street’s bullish view on Lilly’s growth outlook and drug demand. Eli Lilly and Company (NYSE:LLY) Given New $1,500.00 Price Target at Royal Bank Of Canada
• Positive Sentiment: Lilly announced new Alzheimer’s disease research presentations for AAIC 2026, including data on Kisunla and P-tau217 blood tests, highlighting a broader pipeline beyond weight-loss drugs. Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
• Positive Sentiment: Canadian regulators gave a positive recommendation for Lilly’s eczema treatment, adding another potential growth driver outside obesity and diabetes. Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
• Neutral Sentiment: Tampa General Hospital sued Eli Lilly over alleged removal of 340B discounts, creating a legal and pricing overhang, though the financial impact is still uncertain. Tampa General sues Eli Lilly for allegedly pulling 340B discounts

Eli Lilly and Company Stock Performance

LLY stock opened at $1,215.41 on Friday. The company has a market cap of $1.14 trillion, a P/E ratio of 43.18, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock’s fifty day moving average price is $1,091.91 and its 200-day moving average price is $1,032.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 35.81 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Royal Bank Of Canada upped their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their target price for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,260.33.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.